NYSE:NVTA - Invitae Stock Price, Price Target & More

Invitae trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVTA."

Invitae (NYSE:NVTA) announced its earnings results on Wednesday, May, 9th. The medical research company reported ($0.66) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.61) by $0.05. The medical research company earned $27.67 million during the quarter, compared to the consensus estimate of $26.86 million. Invitae had a negative net margin of 154.96% and a negative return on equity of 127.38%. The company's revenue was up 167.6% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.64) EPS. View Invitae's Earnings History.

Invitae is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Invitae.

4 brokerages have issued 12-month target prices for Invitae's shares. Their forecasts range from $9.00 to $15.00. On average, they expect Invitae's stock price to reach $11.00 in the next twelve months. View Analyst Ratings for Invitae.

Some companies that are related to Invitae include Genomic Health (GHDX), Natera (NTRA), RadNet (RDNT), CareDx (CDNA), Enzo Biochem (ENZ), Veracyte (VCYT), Miragen Therapeutics (MGEN), PotNetwork (POTN), Celcuity (CELC), Psychemedics (PMD), Fulgent Genetics (FLGT), First Choice Healthcare Solutions (FCHS), Cancer Genetics (CGIX), OpGen (OPGN) and Biocept (BIOC).

(NVTA) raised $76 million in an initial public offering on Thursday, February 12th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan served as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers.

Press coverage about NVTA stock has trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Invitae earned a news sentiment score of 0.13 on Accern's scale. They also gave headlines about the medical research company an impact score of 43.79 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

Invitae's stock is owned by a number of of retail and institutional investors. Top institutional investors include ARK INVESTMENT MANAGEMENT LLC (10.84%), WELLINGTON MANAGEMENT PORTFOLIOS (DUBLIN) PUBLIC LTD COMPANY (5.23%), BlackRock Inc. (5.15%), Redmile Group LLC (3.18%), Rock Springs Capital Management LP (2.08%) and CVI Holdings LLC (0.67%). Company insiders that own Invitae stock include Bros Advisors Lp Baker, E Lee Bendekgey, Geoffrey Crouse, Katherine Stueland, Patty Dumond, Randal W Scott, Robert L Nussbaum, Sean E George, Shelly D Guyer and Thomas Brida. View Institutional Ownership Trends for Invitae.

NVTA stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Redmile Group LLC and Schwab Charles Investment Management Inc.. Company insiders that have sold Invitae company stock in the last year include E Lee Bendekgey, Katherine Stueland, Patty Dumond, Robert L Nussbaum, Sean E George, Shelly D Guyer and Thomas Brida. View Insider Buying and Selling for Invitae.

NVTA stock was purchased by a variety of institutional investors in the last quarter, including CVI Holdings LLC, BlackRock Inc., Victory Capital Management Inc., Rock Springs Capital Management LP, Blair William & Co. IL, Dimensional Fund Advisors LP, Gamco Investors INC. ET AL and Teton Advisors Inc.. Company insiders that have bought Invitae stock in the last two years include Bros Advisors Lp Baker, Geoffrey Crouse and Randal W Scott. View Insider Buying and Selling for Invitae.

Shares of NVTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of NVTA stock can currently be purchased for approximately $7.27.

Invitae has a market capitalization of $488.58 million and generates $68.22 million in revenue each year. The medical research company earns $-123,380,000.00 in net income (profit) each year or ($2.65) on an earnings per share basis. Invitae employs 594 workers across the globe.

Invitae's mailing address is 1400 16th Street, SAN FRANCISCO CA, 94103. The medical research company can be reached via phone at 415-374-7782 or via email at [email protected]